Samjin Pharmaceutical Appoints Sangjin Kim as New President Overseeing Management

Securing Growth Engines through Recruitment of a Professional Manager
Full Commitment to Strengthening Future Competitiveness

Sangjin Kim, President of Samjin Pharmaceutical. Photo by Samjin Pharmaceutical

Samjin Pharmaceutical announced that it has newly appointed Sangjin Kim as President to oversee overall management. This appointment is a strategic decision aimed at securing new growth engines and enhancing the company's future competitiveness through the recruitment of a professional manager.

The new President, Sangjin Kim, joined Janssen Korea in 1991, later serving as President of Janssen Hong Kong in 2006, President of Janssen Taiwan in 2008, and President of Janssen Korea in 2011. He continued to build extensive experience and expertise across the industry, holding positions such as Vice President of Handok in 2013 and CEO of Samil Pharmaceutical in 2018.

With the addition of Sangjin Kim, Samjin Pharmaceutical expects to maximize its management capabilities and secure new growth drivers in key areas such as global business expansion and new product development.

The new President, Sangjin Kim, stated, "I feel a great sense of responsibility as I join the management team of Samjin Pharmaceutical, which has established a solid position in the domestic pharmaceutical industry through its various business areas," and added, "Based on the experience and capabilities I have accumulated throughout the pharmaceutical industry, I will do my utmost to identify future growth engines and strengthen global competitiveness so that Samjin Pharmaceutical can take another leap forward."

This content was produced with the assistance of AI translation services.